Pharmaceutical

Request for TOC Request for Sample
BUY NOW

North America Immunoassay-Gamma Counters Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | North America | 350 Pages | No of Tables: 109 | No of Figures: 49

Report Description

North America Immunoassay-Gamma Counters Market, By Product Type (Automated, Manual/ Semi-Automated), Well (Multi-well, Single-well), Application (Radio Immunoassays, Nuclear Medicine Assays, Others), Disease Condition (Cancer Biomarker, Infectious Diseases, Therapeutic Drug Monitoring, Endocrine Hormones, Allergy, Neonatal Screening, Cardiac Markers, Auto Immune Disease, Others), Purchase Mode (Out-right Purchase, Rental Purchase), End User (Laboratory, Hospitals, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Blood banks, Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028.

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: North America Immunoassay-Gamma Counters Market

North America immunoassay-gamma counters market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.3% in the forecast period of 2021 to 2028 and is expected to reach USD 38.85 million by 2028. Increasing prevalence of chronic diseases, and increasing adoption of nuclear medicine are the major drivers which propelled the demand of the market in the forecast period.

An immunoassay is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody or an antigen. The biochemical test is carried out through a device known as “Gamma Counter”. A gamma counter is an instrument to measure gamma radiation emitted by a radionuclide. Unlike survey meters, gamma counters are designed to measure small samples of radioactive material, typically with automated measurement and movement of multiple samples. Growing research and development expenditures, increasing healthcare expenditure, and rising patient awareness towards chronic disease treatment is expected to provide a lucrative growth opportunity for the market. However, high cost of gamma counters, and risk of gamma radiation are the factors expected to restraint the market growth in the forecast period.

The immunoassay-gamma counters market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

North America Immunoassay-Gamma Counters Market Scope and Market Size  

Immunoassay gamma counters market is segmented on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product type, North America immunoassay-gamma counters market is segmented into automated, manual/semi-automated. In 2021 automated segment is expected to dominate the market due to lower operating costs, and improved work safety.
  • On the basis of well, North America immunoassay-gamma counters market is segmented into multi-well, single-well. In 2021, the multi-well segment is expected to dominate the market because of accurate measurements, and ability to produce higher spectra levels in short period of time.
  • On the basis of application, North America immunoassay-gamma counters market is segmented into radio immunoassays, nuclear medicine assays, others. In 2021, radio immunoassays is expected to dominate the market due to relative simplicity, and higher sensitivity
  • On the basis of disease condition, North America immunoassay-gamma counters market is segmented into cancer biomarker, infectious diseases, therapeutic drug monitoring, endocrine hormones, allergy, neonatal screening, cardiac markers, auto immune disease, others. In 2021, the cancer biomarkers segment is expected to dominate the market due to its use in estimating risk of disease, and integral to drug development
  • On the basis of purchase mode, the North America immunoassay-gamma counters market is segmented into out-right purchase, rental purchase. In 2021, the out-right purchase segment is expected to dominate the market due to reduced price or total cost, and securing greater value from supplier
  • On the basis of end user, the North America immunoassay-gamma counters market is segmented into laboratory, hospitals, research & academic institutes, pharmaceutical & biotechnology companies, blood banks, others. In 2021, the laboratory segment is expected to dominate the market due to regulatory compliance, and cost savings.
  • On the basis of distribution channel, the North America immunoassay-gamma counters market is segmented into direct sales and third party distributors. In 2021, direct tender segment is expected to dominate the market because of improved supplier management, and to achieve target costs.

Immunoassay-Gamma Counters Market Country Level Analysis

The immunoassay-gamma counters market is analyzed and market size information is provided on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel as referenced above.

The countries covered in the immunoassay-gamma counters market report are U.S., Canada and Mexico.

The U.S. is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of accurate measurements, and ability to produce higher spectra levels in short period of time.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Product Approvals and Novelty in Diagnosis Procedures are Boosting the Market Growth of Immunoassay-Gamma Counters

Immunoassay gamma counters market also provides you with detailed market analysis for every country growth in bacteriophage therapy industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Immunoassay-Gamma Counters Market Share Analysis

Immunoassay gamma counters market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to immunoassay-gamma counters market.

The major companies operating in the North America immunoassay-gamma counters market are Hidex Oy, Perkin Elmer Inc, Berthold Technologies GmbH & Co. KG, ENERSYS Co. Ltd, Shinjin Medics Inc, LabLogic Systems Ltd, among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the immunoassay-gamma counters market.

For instance,

  • In July 2021, PerkinElmer Inc. announced that the company is further looking to expand their footprints in India by relying on innovative products. The new products will be launched in various streams such as science, pharma, and food testing. This has helped the company to expand its global presence

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the immunoassay-gamma counters market which also provides the benefit for organization to improve their offering for immunoassay-gamma counters.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTES FIVE FORCES

5 REGULATORY GUIDELINES FOR IMMUNOASSAY-GAMMA COUNTERS

5.1 U.S. REGULATORY GUIDELINES FOR IMMUNOASSAYS-GAMMA COUNTERS

5.2 EUROPE REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

5.3 JAPAN REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

5.4 CHINA REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASE IN PREVALENCE OF CHRONIC DISEASES

6.1.2 PRODUCT APPROVAL

6.1.3 INCREASE IN ADOPTION OF NUCLEAR MEDICINE

6.1.4 NOVELTY IN DIAGNOSIS PROCEDURES

6.1.5 UPGRADING GAMMA TECHNOLOGY

6.2 RESTRAINTS

6.2.1 HIGH COST OF GAMMA COUNTER

6.2.2 RISK OF GAMMA RADIATION

6.2.3 STRINGENT REGULATION OF CLINICAL USE OF GAMMA COUNTER

6.2.4 PRODUCT RECALL

6.3 OPPORTUNITIES

6.3.1 GROWING RESEARCH AND DEVELOPMENT EXPENDITURE

6.3.2 INCREASE IN HEALTHCARE EXPENDITURE

6.3.3 RISE IN PATIENTS AWARENESS TOWARDS CHRONIC DISEASE TREATMENT

6.4 CHALLENGES

6.4.1 CHALLENGES IN USING GAMMA COUNTER

6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7 IMPACT OF COVID-19 ON NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET

7.1 IMPACT ON THE PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVES BY MANUFACTURERS

7.5 CONCLUSION

8 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE

8.1 OVERVIEW

8.2 AUTOMATED

8.2.1 RADIOIMMUNOASSAYS

8.2.1.1 RIA

8.2.1.2 IRMA

8.2.2 NUCLEAR MEDICINE ASSAYS

8.2.2.1 GFR (Glomerular FILTRATION RATE)

8.2.2.2 Gamma glutamyl transferase (ggt)

8.2.2.3 red cell mass and plasma volume test

8.2.2.4 THE SCHILLING TEST

8.2.2.5 others

8.2.3 OTHERS

8.3 MANUAL/SEMI-AUTOMATED

8.3.1 RADIOIMMUNOASSAYS

8.3.1.1 RIA

8.3.1.2 IRMA

8.3.2 NUCLEAR MEDICINE ASSAYS

8.3.2.1 GFR (Glomerular FILTRATION RATE)

8.3.2.2 Gamma glutamyl transferase (ggt)

8.3.2.3 red cell mass and plasma volume test

8.3.2.4 THE SCHILLING TEST

8.3.2.5 others

8.3.3 OTHERS

9 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL

9.1 OVERVIEW

9.2 MULTI-WELL

9.3 SINGLE-WELL

10 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 RADIO IMMUNOASSAYS

10.2.1 RIA

10.2.2 IRMA

10.3 NUCLEAR MEDICINE ASSAY

10.3.1 GFR (GLOMERULAR FILTRATION RATE)

10.3.2 GAMMA-GLUTAMYL TRANSFERASE

10.3.3 RED CELL MASS AND PLASMA VOLUME TEST

10.3.4 THE SCHILLING TEST

10.3.5 OTHERS

10.4 OTHERS

11 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION

11.1 OVERVIEW

11.2 CANCER BIOMARKERS

11.2.1 CARBOHYDRATE ANTIGEN 125 (CA125)

11.2.2 CARBOHYDRATE ANTIGEN 19-9

11.2.3 CARCINO EMBRYONIC ANTIGEN

11.2.4 ALPHA-FETOPROTEIN

11.2.5 OTHERS

11.3 INFECTIOUS DISEASES

11.4 THERAPEUTIC DRUG MONITORING

11.5 ENDOCRINE HORMONES

11.6 ALLERGY

11.7 NEONATAL SCREENING

11.8 CARDIAC MARKERS

11.9 AUTOIMMUNE DISEASE

11.1 OTHERS

12 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE

12.1 OVERVIEW

12.2 OUTRIGHT PURCHASE

12.3 RENTAL PURCHASE

13 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 THIRD PARTY DISTRIBUTORS

14 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 LABORATORY

14.4 BLOOD BANKS

14.5 RESEARCH AND ACADEMIC INSTITUTES

14.6 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES

14.7 OTHERS

15 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY GEOGRAPHY

15.1 NORTH AMERICA

15.1.1 U.S.

15.1.2 CANADA

15.1.3 MEXICO

16 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PERKINELMER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 BRETHOLD TECHNOLOGIES GMBH & CO.KG

18.2.1 COMPANY SNAPSHOT

18.2.2 COMPANY SHARE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENTS

18.3 LABLOGIC SYSTEMS LTD.

18.3.1 COMPANY SNAPSHOT

18.3.2 COMPANY SHARE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 SHIN JIN MEDICS INC.

18.4.1 COMPANY SNAPSHOT

18.4.2 COMPANY SHARE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 HIDEX OY

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENTS

18.6 LABORATORY TECHNOLOGIES. INC.

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENT

18.7 ENERSYS, CO.LTD.

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

18.8 MIRION TECHNOLOGIES (CAPINTEC),INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS

TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC

TABLE 3 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 4 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 5 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 6 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 7 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 8 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 9 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 10 NORTH AMERICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 11 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 12 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 13 NORTH AMERICA MULTI-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 14 NORTH AMERICA SINGLE-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 15 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 16 NORTH AMERICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 17 NORTH AMERICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 18 NORTH AMERICA NUCLEAR MEDICINE ASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 19 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 20 NORTH AMERICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 21 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 22 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 23 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 24 NORTH AMERICA INFECTIOUS DISEASES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 25 NORTH AMERICA THERAPEUTIC DRUG MONITORING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ENDOCRINE HORMONES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 27 NORTH AMERICA ALLERGY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 28 NORTH AMERICA NEONATAL SCREENING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 29 NORTH AMERICA CARDIAC MAKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 30 NORTH AMERICA AUTO IMMUNE DISEASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 31 NORTH AMERICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 32 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 33 NORTH AMERICA OUTRIGHT PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 34 NORTH AMERICA RENTAL PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)

TABLE 35 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 36 NORTH AMERICA DIRECT TENDER IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 37 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 38 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 39 NORTH AMERICA HOSPITALS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 40 NORTH AMERICA LABORATORY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 41 NORTH AMERICA BLOOD BANKS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 20152028 (USD MILLION)

TABLE 42 NORTH AMERICA RESEARCH AND ACADEMIC INSTITUTES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 43 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 44 OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 45 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY COUNTRY, 2015-2028 (USD MILLION)

TABLE 46 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 47 NORTH AMERICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 48 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 49 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 50 NORTH AMERICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 51 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 52 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 53 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 54 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 55 NORTH AMERICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 56 NORTH AMERICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 57 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 58 NORTH AMERICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 59 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 60 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 61 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 62 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 63 U.S. AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 64 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 65 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 66 U.S. MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 67 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 68 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 69 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 70 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 71 U.S. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 72 U.S. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 73 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 74 U.S. CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 75 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 76 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 77 U.S. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 78 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 79 CANADA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 80 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 81 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 82 CANADA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 83 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 84 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 85 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 86 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 87 CANADA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 88 CANADA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 89 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 90 CANADA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 91 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 92 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 93 CANADA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

TABLE 94 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 95 MEXICO AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 96 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 97 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 98 MEXICO MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 99 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 100 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)

TABLE 101 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)

TABLE 102 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 103 MEXICO RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 104 MEXICO NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)

TABLE 105 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 106 MEXICO CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)

TABLE 107 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)

TABLE 108 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)

TABLE 109 MEXICO IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID

FIGURE 10 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET

FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS

FIGURE 16 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020

FIGURE 17 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020

FIGURE 21 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE

FIGURE 24 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020

FIGURE 25 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020

FIGURE 29 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)

FIGURE 31 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020

FIGURE 33 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)

FIGURE 35 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020

FIGURE 37 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 39 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020

FIGURE 41 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)

FIGURE 43 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SNAPSHOT (2020)

FIGURE 45 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020)

FIGURE 46 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2021 &2028)

FIGURE 47 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 49 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)

View Infographics

FIGURE 1 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID

FIGURE 10 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION

FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET

FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS

FIGURE 16 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020

FIGURE 17 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)

FIGURE 18 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)

FIGURE 19 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020

FIGURE 21 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)

FIGURE 22 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)

FIGURE 23 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE

FIGURE 24 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020

FIGURE 25 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 26 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)

FIGURE 27 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020

FIGURE 29 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)

FIGURE 30 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)

FIGURE 31 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE

FIGURE 32 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020

FIGURE 33 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)

FIGURE 34 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)

FIGURE 35 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020

FIGURE 37 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 38 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 39 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 40 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020

FIGURE 41 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)

FIGURE 43 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SNAPSHOT (2020)

FIGURE 45 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020)

FIGURE 46 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2021 &2028)

FIGURE 47 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY PRODUCT TYPE (2021-2028)

FIGURE 49 NORTH AMERICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19